Investor profile
UCL Business (UCLB)
CVC
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
UCL Business (UCLB) is the wholly owned commercialisation subsidiary of University College London, dedicated to protecting and commercialising pioneering ideas, innovations and technologies developed at UCL and its partner NHS hospitals. UCLB invests directly in UCL spinout companies at Seed and Series A stage — with initial cheques up to £250k alongside angel syndicates and external investors, and up to £5m across multiple rounds — and co-manages the UCL Technology Fund (with AlbionVC) to invest in IP commercialisation opportunities predominantly in engineering and life sciences that have the potential to generate outstanding societal and market impact. UCLB also provides proof-of-concept grants, therapeutic licensing development funding (£500k–£2m), and a dedicated Social Ventures fund, covering the full spectrum from early lab-stage research to high-growth spinout businesses.
Notable quotes
“We've had great success in commercialising groundbreaking research and finding value when combining our academic and investment expertise.”
“Academics want to get involved because it gives their work real-world impact.”
“London is fizzing with life science innovation, from AI-powered diagnostics to gene therapy and breakthrough cell treatments.”
Team
Katy Bruce
Chief Financial Officer
Dr Richard Fagan
Director of BioPharm
Ana Lemmo Charnalia
Senior Business Manager, Social Ventures
Dr Sara Garcia Gomez
Senior Business Manager
Jessica Bolton-Murray
Head of Project Management
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Engitix | Series A | — | 2026-01-08 |
| Autolus Therapeutics | IPO / Series | $160m | 2018-06-01 |
| Orchard Therapeutics | IPO | $225m | 2018-11-01 |
| Freeline Therapeutics | Series B | $115m | 2018-06-18 |
| Quell Therapeutics | Series B | $156m | 2021-11-29 |
| MeiraGTx | IPO | $75m | 2018-06-12 |
| Achilles Therapeutics | IPO | — | 2021-03-01 |
| Hazy | Seed/Series A | — | 2019-01-01 |
| Echopoint Medical | Series A | $5m | 2024-02-01 |
| Carbon Re | Seed | $1m | 2021-10-01 |
Frequent co-investors
Fit check
Is UCL Business (UCLB) a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit